You are here:

MS in the media - 8 April 2016

Published on

2 - 8 April 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

DMDs and brain atrophy

An analysis of 35 trials found that after two years of treatment, the more powerful disease modifying drugs (Tysabri, Gilenya, Lemtrada and daclizumab) showed a significant slowing of brain tissue loss compared to placebo.  The first line drugs (Copaxone, beta interferon, Aubagio, Tecfidera and laquinimod) reduced the number of relapses but were no better than placebo at slowing tissue loss

Source: MSRA

MS Trust link: MS Decisions (a guide to the disease modifying drugs approved for treating relapsing remitting MS)

Do Paralympians encourage or deter exercise?

Alistair Hignall (who has MS) writes that the level of Paralympic athletes is such that people with disabilities are more likely to be put off exercising than to be encouraged to do so.

Source: Guardian

MS Trust link: Exercise

Beta interferon in children

A study of adolescents with MS in the USA, Italy, Russia, Argentina, France, Canada, Tunisia, and Venezuela found the Americans were more likely to start treatment with beta interferon sooner but also had more relapses.  The Americans were also more likely to be overweight (though data on this was very patchy)

Source: MS News Today

MS Trust link: Childhood MS - could you help us?

Myelitis and MS

Spanish research is trying to identify which people who have myelitis (inflammation of the spinal cord) go on to develop MS and thus if it is possible to start MS treatment at this early stage.  Of the 91 people with myelitis in the study, almost two thirds were diagnosed with MS over the following seven years

Source: MS News Today

MS Trust link: Worried you have MS?

Most PIP appeals are successful

Figures from the Department of Work & Pensions (DWP) show that in the last three months of 2015, three out of five people who appealed against the decision not to award them personal independence payments (PIP) were successful. This equates to 578 successful appeals a week.

Source: Daily Mirror

MS Trust link: Benefits

Switching to rituximab or Gilenya from Tysabri

A Swedish study looked at people switching from Tysabri to either rituximab or Gilenya.  In the 18 months after the switch, the people on rituximab had had fewer relapse, fewer side effects and fewer had stopped treatment than in the Gilenya group

Source: Neurology Adviser

MS Trust link: MS Decisions

The effect of other health conditions

Canadian research found that people with MS had higher rates depression (29%), high blood pressure (17.8%), high cholesterol (12.4%), and anxiety (11.5%).  The interaction of these and MS resulted in low quality of life scores.

Source: Neurology Adviser

MS Trust link: Research into MS and other health conditions - news item from earlier in the study

Print this page